Financial performance 2008/2007
Download Excel table (see terms of use page)
OUR FINANCIAL PERFORMANCE| 2008 | 2007 | 2006 | 2008 compared to 2007 | 2007 compared to 2006 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth $m |
Growth due to exchange effect $m |
Sales $m |
CER growth % |
Reported growth % |
CER growth % |
Reported growth % |
| Casodex | 1,258 | (161) | 84 | 1,335 | 74 | 55 | 1,206 | (12) | (6) | 6 | 11 |
| Arimidex | 1,857 | 69 | 58 | 1,730 | 151 | 71 | 1,508 | 4 | 7 | 10 | 15 |
| Zoladex | 1,138 | (31) | 65 | 1,104 | 39 | 57 | 1,008 | (3) | 3 | 4 | 10 |
| Iressa | 265 | 8 | 19 | 238 | (1) | 2 | 237 | 3 | 11 | – | – |
| Faslodex | 249 | 25 | 10 | 214 | 18 | 10 | 186 | 12 | 16 | 10 | 15 |
| Nolvadex | 85 | (5) | 7 | 83 | (8) | 2 | 89 | (6) | 2 | (9) | (7) |
| Abraxane® | 64 | 2 | – | 62 | 44 | – | 18 | 3 | 3 | 244 | 244 |
| Ethyol | 28 | (15) | – | 43 | 43 | – | – | n/m | n/m | n/m | n/m |
| Other | 10 | (1) | 1 | 10 | (1) | 1 | 10 | (10) | – | (10) | – |
| Total | 4,954 | (109) | 244 | 4,819 | 359 | 198 | 4,262 | (2) | 3 | 8 | 13 |
PERFORMANCE 2008
Reported performance
Sales in Oncology increased by 3% on a reported basis to $4,954 million up from $4,819 million in 2007.
Performance – CER growth rates
Sales in the Oncology therapy area were down 2% at CER. Arimidex sales were up 4% to $1,857 million. In the US, Arimidex sales were up 9% to $754 million. In other markets, sales increased by 1% to $1,103 million.
Casodex sales decreased by 12% to $1,258 million, with sales in the US down by 2% and sales in other markets down by 15%.
Iressa sales for the year were up 3% as growth in China and other Emerging Markets more than offset the 3% decline in sales in Japan.
Faslodex sales were up 12% with a 5% increase in the US and 18% in other markets.
PERFORMANCE 2007
Reported performance
Oncology sales increased by 13% to reach $4,819 million in 2007, compared with $4,262 million in 2006.
Performance – CER growth rates
Oncology sales grew by 8% at CER. Arimidex sales reached $1,730 million, up 10%. In the US, sales of Arimidex rose by 13% to $694 million. Total prescriptions for Arimidex increased nearly 5.3% compared with 1.3% growth in the market for hormonal treatments for breast cancer. Arimidex sales in other markets increased by 8% to $1,036 million. Sales for the full year were up 6% in Western Europe and increased 9% in Japan.
Casodex sales increased by 6% to $1,335 million. Sales in the US for the full year were up 1% to $298 million. Sales in other markets, which accounted for more than 75% of product sales, were up 8%, on 6% growth in Western Europe and 13% sales growth in Japan.
Iressa sales were unchanged for the full year. Sales in Japan increased 4% for the year; sales in China were up 24%.
Faslodex sales increased 10% to $214 million for the full year, on growth of 3% in the US and 18% sales growth in other markets.
